MEDEZE Reports 2025 Net Profit of THB 196 Million with Revenue of THB 776 Million Confident in International Standards and Advanced Medical Trends to Drive Future Growth
Medeze Group Public Company Limited (MEDEZE) reported a net profit of THB 196.38 million for 2025, with total revenue reaching THB 776.41 million. The company continues to maintain a strong domestic customer base while accelerating efforts to explore alternative markets to replace Cambodia. MEDEZE is also preparing to capture growth opportunities from Advanced Therapy Medicinal Products (ATMPs). The company remains confident that its international service standards and the growing momentum of advanced medical technologies will support its long-term expansion.
Dr. Veerapol Khemarangsan, Chief Executive Officer of Medeze Group Public Company Limited (MEDEZE), revealed that the company recorded total revenue of THB 776.41 million and a net profit of THB 196.38 million for the 2025 fiscal year. The company’s primary revenue source continued to be cord tissue-derived stem cells, which accounted for 47% of total revenue in 2025.
Despite current economic conditions affecting consumer purchasing power, the Group has successfully maintained a loyal core customer base. This reflects the strong trust customers place in MEDEZE’s products and services, which remain a top priority for many clients who continue to retain access to the company’s services.
The company also announced a cash dividend payment of THB 0.08 per share, derived from net profits for the operating period 1 January 2025 to 31 December 2025, as well as retained earnings. The ex-dividend date (XD) is scheduled for 29 April 2026, with dividend payment set for 19 May 2026.
Throughout 2025, the company continued to expand its business operations, particularly in the development of Advanced Therapy Medicinal Products (ATMPs). One key initiative is the “ATMPs Sandbox” project, which has shown steady progress through collaboration with the Ministry of Public Health and medical institutions. Together, they organized the “Thailand ATMP Roadmap 2025” conference under the theme “Fast Track to Access & Innovation: Fastest in ASEAN.”
The initiative aims to accelerate the development of ATMP products and establish a comprehensive ecosystem—from research and clinical trials to real-world applications—within a clearly defined timeframe. This effort will create greater opportunities for collaboration between the public and private sectors, ultimately leading to highly effective treatments for complex diseases.
Most importantly, it seeks to establish standardized research processes that foster innovation, enable Thai citizens to access ATMP treatments more broadly at reasonable costs, and elevate Thailand’s position from a consumer of pharmaceutical and medical products to a producer and innovator capable of developing high-quality, accessible, and safe medical technologies.
Participation in these initiatives reflects MEDEZE’s strong commitment to supporting the Thailand ATMP Roadmap while strengthening the healthcare ecosystem in research, innovation, and medical development to support the sustainable growth of the health economy in the future.
In addition, the company has signed a Memorandum of Understanding (MOU) with Identity Group Co., Ltd., one of Thailand’s leading laser and dermatology centers. The partnership aims to jointly develop services in Regenerative Beauty & Anti-Aging, promoting healthcare and aesthetic treatments based on regenerative medicine through medically sound, safe, and verifiable procedures. This collaboration is also expected to elevate Thailand’s healthcare and aesthetic services to international standards while creating new growth opportunities for MEDEZE in the future.
For more information, please visit: https://www.medezegroup.com/th/
IR Press Releases
